Post-Licensure Observational Study of the Safety of GARDASIL in Males.

Trial Profile

Post-Licensure Observational Study of the Safety of GARDASIL in Males.

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 23 Mar 2017

At a glance

  • Drugs Human papillomavirus vaccine recombinant quadrivalent Merck (Primary)
  • Indications Human papillomavirus infections
  • Focus Adverse reactions
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 12 May 2016 Planned End Date changed from 1 Jun 2017 to 1 Jun 2018.
    • 12 May 2016 Planned primary completion date changed from 1 Jun 2017 to 1 Jun 2018.
    • 11 Apr 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top